Concepedia

Makoto Nishio

MN

Statistics

Publications

6

Citations

88

H-Index

6

Active since

2024

Affiliations

Japanese Foundation For Cancer Research(Current)

Memorial Sloan Kettering Cancer Center

Chris O’Brien Lifehouse

Yonsei University

The University of Texas MD Anderson Cancer Center

Makoto Nishio is an author at Japanese Foundation For Cancer Research specializing in oncology, non-small cell lung cancer therapy, and medicine.

Publications per year

2024–2025

6

Publications

6

BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Yuichiro Ohe, Baohui Han, Makoto Nishio et al. · Journal of Clinical Oncology · 2024 · 23 citations

, , +17

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy

Natasha B. Leighl, Luis Paz‐Ares, Delvys Rodríguez‐Abreu et al. · Journal of Thoracic Oncology · 2025 · 18 citations · Full text

, , +16

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Matthew Krebs, Byoung Chul Cho, Sandrine Hiret et al. · Journal of Thoracic Oncology · 2025 · 15 citations · Full text

, , +16

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Benjamin Solomon, Ibiayi Dagogo‐Jack, Se-Hoon Lee et al. · JTO Clinical and Research Reports · 2024 · 12 citations · Full text

, , +6

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC.

Marcelo V. Negrão, Kathryn C. Arbour, Timothy F. Burns et al. · Journal of Clinical Oncology · 2024 · 10 citations

, , +9

1–5 of 6